Prediction of natalizumab anti-drug antibodies persistency.

about

Prediction of natalizumab anti-drug antibodies persistency.

Item

http://www.wikidata.org/entity/Q48237799

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Prediction of natalizumab anti-drug antibodies persistency.

@en

Prediction of natalizumab anti-drug antibodies persistency.

@nl

type

Item

label

Prediction of natalizumab anti-drug antibodies persistency.

@en

Prediction of natalizumab anti-drug antibodies persistency.

@nl

prefLabel

Prediction of natalizumab anti-drug antibodies persistency.

@en

Prediction of natalizumab anti-drug antibodies persistency.

@nl

P1476

Prediction of natalizumab anti-drug antibodies persistency

@en

P2093

ABIRISK consortium

http://www.w3.org/2001/XMLSchema#string

Anders Sjödin

http://www.w3.org/2001/XMLSchema#string

Anna Fogdell-Hahn

http://www.w3.org/2001/XMLSchema#string

Anna Lauren

http://www.w3.org/2001/XMLSchema#string

Claudia Sievers

http://www.w3.org/2001/XMLSchema#string

Louis Christodoulou

http://www.w3.org/2001/XMLSchema#string

Malin Ryner

http://www.w3.org/2001/XMLSchema#string

Marc Pallardy

http://www.w3.org/2001/XMLSchema#string

Marlies Jank

http://www.w3.org/2001/XMLSchema#string

Mary Birchler

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Extended interval dosing of natalizumab in multiple sclerosis.

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.

Pathology of multiple sclerosis and related inflammatory demyelinating diseases.

Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.

Disease activity return after natalizumab cessation in multiple sclerosis.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials.

P304

392-398

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1352458517753721

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Finn Sellebjerg

R S Liblau

Florian Deisenhammer

P577

2018-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29336205

http://www.w3.org/2001/XMLSchema#string